Genmab and Abbvie submit new cancer drug for FDA and EMA approval
Cancer candidate epcoritamab, which is developed by Genmab and Abbvie, is now ready to be assessed by the regulatory authorities of the EU and USA. (Updated)
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Genmab and Abbvie have submitted cancer treatment candidate epcoritamab for regulatory review by the US Food and Drug Administration, FDA, and the European Medicines Agency, EMA, a Friday press release announces.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab has a worthy successor to Darzalex, bank says
For subscribers
Genmab upgrades 2022 guidance
For subscribers
